Bristol Myers Squibb Receives European Commission Approval For Opdivo With Chemotherapy As Neoadjuvant Treatment Of Resectable Non-Small Cell Lung Cancer At High Risk Of Recurrence In Patients With Tumor Cell PD-L1 Expression ≥1%
Portfolio Pulse from Benzinga Newsdesk
Bristol Myers Squibb has received approval from the European Commission for its drug Opdivo, in combination with chemotherapy, as a neoadjuvant treatment for resectable non-small cell lung cancer at high risk of recurrence in patients with tumor cell PD-L1 expression ≥1%.
June 29, 2023 | 11:00 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
The approval of Opdivo by the European Commission could potentially increase Bristol Myers Squibb's market share in the cancer treatment sector, which may positively impact its stock price in the short term.
The approval of a new drug or treatment often leads to increased sales and revenue for the company, which can positively impact the stock price. Given that this approval is for a high-risk cancer treatment, it could potentially lead to a significant increase in market share for Bristol Myers Squibb.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100